Electro-Optical Sciences announces agreement with L’Oreal
-
- March
- 30
Electro-Optical Sciences Inc. announced today that it has signed an agreement with L’Oreal to study the feasibility of using EOS’ imaging technology for the evaluation of pigmented skin lesions of cosmetic importance.
EOS, based in Irvington, is a medical device company that focuses on the early detection of melanoma, the rarest but most deadly form of skin cancer.
The company has granted L’Oreal an option to use its technology in research funded by L’Oreal.
MelaFind, its flagship product, uses a hand-held imaging device that to capture images of suspicious pigmented skin lesions and extract data. The data is then analyzed against a proprietary database of melanomas and benign lesions to provide information physicians and a recommendation on whether the lesion should be biopsied.
“We are delighted to collaborate with the L’Oreal researchers in Paris who are acknowledged worldwide leaders in the science of skin conditions,â€? said Dr. Joseph V. Gulfo, president and chief executive officer of EOS, in a written statement. “The work that we will perform with L’Oreal is based on the years of clinical research that we have undertaken and experience that we have amassed in the development of MelaFind. Important multi-spectral imaging-based diagnostic systems for cosmetic conditions may result directly from this collaboration.â€?
EOS shares closed at $5.15, up 15 cents, or 3 percent in trading on the Nasdaq.
For more information on EOS, visit its Web site (www.eosciences.com).
This entry was posted
on Friday, March 30th, 2007 at 4:42 pm by Alison Bert.
You can follow any responses to this entry through the RSS 2.0 feed.
Share and Enjoy: 
| 
Print
| 
Email
